骨髓增生异常综合征患者血清sICAM-1水平及其临床意义

目的探讨骨髓增生异常综合症（MDS）患者血清sICAM-1水平的改变及其临床意义。方法用ELISA法测定25例MDS患者治疗前及15例对照组患者sICAM-1水平，并监测MDS患者治疗后的sICAM-1水平。结果MDS中RA、RAS患者治疗前后sICAM-1水平与对照组及RAEB患者治疗后好转患者sICAM-1水平相比无显著差异（P〉0．05），RA、RAS与RAEB、RAEB与对照组及RAEB治疗后好转患者sICAM-1水平相比有显著差异（P〈0．05）。结论sICAM-1水平测定有助于MDS中RAEB与RA、RAS的鉴别，也有助于MDS的疗效判定。

The sICAM-1 Level of the Patients with Myelodysplastic Syndrome and the Clinical Value

Objective To discuss the change of sICAM - 1 of the patients with myelodysplastic syndrome （ MDS ） and its clinical value. Methods The sICAM - 1 levels of 25 cases with myelodysplastic syndrome before treatment and that of 15 normal controllers were measured with ELISA and the levels after treatment were monitored. Results The sICAM - 1 level of the patients with MDS - RA and MDS - RAS before and after treatment was not obviously different from that of the control and that of the patients with RAEB who had improvement after treatment （ P 〉 0.05 ） while there existed a significant difference of sICAM - 1 level between the patients with RA, RAS and the control and the patients with RAEB who had improvement after treatment （ P 〉 0.05 ）. Conclusions The measurement of sCAM - 1 is helpful to the differentiation between RAEB and RA, and is also helpful in determining the curative effect in treating MDS.